Biofrontera Stock
Biofrontera Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- United States
- CEO
- Hermann Lübbert
- Employees
- 89
- Market cap
- $12 M
- IPO
- 29/10/2021
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are…
Biofrontera stock: price history
1D
-3.0%
1W
-15.3%
1M
-32.1%
6M
-25.3%
YTD
+44.1%
1Y
-17.0%
2Y
+8.1%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~67% stronger price swings than usual
Ask the agents about Biofrontera
Analyst assessment of Biofrontera
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 19/05/2026
Biofrontera stock metrics
P/E
-1.37
P/B
1.78
EV/EBITDA
-2.77
RETURN ON EQUITY
-10.1%
NET MARGIN
-5.0%
DEBT/EQUITY
1.26
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.6%
FLOAT SHARES
11,816,388
AVG. DAILY VOLUME (30D)
577,813
Insider transactions (SEC)
Leffler Eugene Frederick
Luebbert Hermann
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Biofrontera stock
What does Biofrontera do?
Biofrontera Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Hermann Lübbert, the company employs around 89 people.
The IPO was on 29/10/2021; the stock trades on NASDAQ under the ticker BFRI.
What do analysts say about Biofrontera stock?
1 analysts rate the stock, the consensus is Buy (as of 19/05/2026).
This is an external assessment, not a statement by Market Jury.
When does Biofrontera report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 67% stronger than usual.
Does Biofrontera pay a dividend?
No, Biofrontera currently does not pay a dividend.
Which stocks are comparable to Biofrontera?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck &.
How can I get Biofrontera stock analyzed?
Clicking "Analyze stock" lets five strategies assess Biofrontera against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.